|
PF-10638 |
RECORMON-2000, 2000 UI Liofilizado para uso parenteral |
2006-03-06 |
|
Roche Diagnostics GmbH |
Alemania
|
Amicelco |
Colon S.A. |
Agencias J.i. Cohen |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-24255 |
BONADRONAT 1mg/mL. Solucion Inyectable. |
2006-06-21 |
|
Roche Diagnostics GmbH |
Alemania
|
Amicelco |
Colon S.A. |
Agencias J.i. Cohen |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-26740 |
RECORMON 4000 UI/0.3 mL Solucion inyectable |
2011-07-30 |
|
F-Hoffmann-La Roche, S. A. / Suiza |
Alemania
|
Agencias J.I. Cohen |
Droguería Colón |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-23761 |
RECORMON 2000 UI/0.3 mL Solución Inyectable |
2026-02-02 |
|
F-Hoffmann-La Roche, S. A. / Suiza |
Alemania
|
J.I.Cohen, S.A. |
Agencias J.I. Cohen |
Agencias J. I. Cohen |
Centro Distribuidor, S.A. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-24705 |
RECORMON 10,000 UI/0.6 mL. Solucion Inyectable |
2007-02-06 |
|
Roche Diagnostics GmbH |
Alemania
|
Amicelco |
Colon S.A. |
Agencias J.i. Cohen |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-19509 |
COREG 12.5 mg comprimidos |
2008-02-09 |
|
Gp Grenzach Produktions Gmbh |
Alemania
|
Amicelco |
Colon S.A. |
Agencias J.i. Cohen |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-22430 |
RECORMON MULTIDOSIS 50,000 UI Liofilizado y solucion para uso parenteral |
2019-11-18 |
|
F. Hoffmann-La Roche, S.A. |
Alemania
|
J.I.Cohen, S.A. |
Agencias J.I. Cohen |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-34366 |
BONDRONAT 1 mg/mL solucion inyectable |
2024-11-15 |
|
Atnahs Pharma Uk Limited |
Alemania
|
J.I.Cohen, S.A. |
Agencias J. I. Cohen |
Droguería Colón |
Centro Distribuidor, Sociedad Anónima |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-34391 |
RECORMON 30,000 UI / 0.6 mL Solución inyectable |
2024-11-20 |
|
F. Hoffmann-La Roche, S.A. |
Alemania
|
J.I.Cohen, S.A. |
Agencias J. I. Cohen |
Centro Distribuidor, Sociedad Anónima |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PF-32772 |
UNAT 20 mg/ 4mL Solucion Inyectable |
2014-05-27 |
|
F-Hoffmann La Roche Ltd. |
España
|
Colon S.A. |
Agencias J.i. Cohen |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|